The company said it's selling 155 million more shares than initially expected, making its record-shattering IPO almost $13 billion larger.
Rockstar’s long-awaited game earned a near-perfect score ahead of its U.S. launch, adding to the case for Take-Two.
Trump and Xi are expected to discuss trade and chip export controls in Shenzhen. The allegations involving Nvidia may go unaddressed.
Electricity demand is growing, even without AI data centers. Somebody has to supply the infrastructure that supports it.
Long Read
Recurring services revenue and a pending $4.2 billion Equiniti deal are helping Bullish weather sluggish digital-asset volumes.
2 minute read
The retailer’s turnaround is bearing fruit.
3 minute read
November 16, 2026
Nvidia’s stock hasn’t worked for a while now, and that was with Jensen Huang as CEO. His surprise resignation is a chance for investors to reassess.
Long Read
The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
3 minute read
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.
2 minute read
Optimists cite robust earnings growth; the pessimists see a bubble in danger of bursting. Plus, pro forecasts for rates, international markets, the midterm, and more.
Long Read
In our latest Big Money poll, professional investors are more upbeat than six months ago and see plenty of opportunities for stocks. Where they’re putting money to work.
Long Read
Carriers’ shares got a boost on Monday, as the worst of the weekend’s travel chaos looks to be over.
1 minute read
Buying out Double Eagle’s 40% stake lets Diamondback capture more revenue from wells it was already planning to drill.
3 minute read
The tech-heavy S&P 500 has underperformed small-cap value stocks this year. Given less tech exposure, cheaper valuations, and a higher yield, smaller stocks may deserve a bigger allocation in investor portfolios.
3 minute read
Recent market volatility has highlighted the value of defensive names in stock portfolios. We asked investment professionals to name their favorites.
Long Read
Barron's ranks the best advisors, firms, and teams in the country. The goal is to shine a spotlight on the nation's best financial advisors, with an eye toward raising standards in the industry.
Are you ready to search for a financial advisor? We'll match you with advisors who can help.
Includes common stocks, ADRs and REITs listed on NYSE, Nasdaq or NYSE American with a prior day close of $2 a share or higher and volume of at least 50,000
| Company (Ticker) | Change Percent | Price |
|---|---|---|
| Akanda Corp. (AKAN) | 96.59% | $4.03 |
| SkyAI Inc. (SKYA) | 90.32% | $4.13 |
| Cue Biopharma Inc. (CUE) | 68.20% | $4.76 |
| ClearOne Inc. (CLRO) | 46.19% | $6.90 |
| Mega Matrix Inc. (MPU) | 33.96% | $2.84 |